• President Trump will announce a major expansion of TrumpRx.gov, adding more drugs and deeper discounts.
  • The platform now includes 80 medications, with companies like Merck and Sanofi offering cuts of up to 92%.
  • Participation is tied to tariff exemptions, creating a new public-private pricing model.

TrumpRx Expansion Expected to Boost Access

President Donald Trump is poised to announce a significant expansion of TrumpRx.gov, the White House-launched platform offering discounted prescription drugs, according to a CNBC reporter. The move comes as the site has already grown from 40 to 80 medications since its February 2026 launch, with major pharmaceutical companies signing on.

“We’re seeing unprecedented participation,” said a White House spokesperson, noting that 16 of the 17 largest pharma companies have joined. The platform leverages a unique tariff-exchange model: drugmakers receive exemptions in exchange for lowering prices for Medicaid and extending those discounts to cash-paying consumers. Merck, for instance, cut the price of a Type 2 diabetes drug by 74%, from $330 to $84.57, while Sanofi marked down its insulin Toujeo by 92%, to $35.

A Shift in Drug Pricing Strategy

The expansion targets high-cost medications, including diabetes, tuberculosis, blood thinners, and weight-loss drugs like Ozempic and Wegovy. Johnson & Johnson joined late last month, adding four drugs. “This ends decades of overpayment,” Trump said at a White House event, framing the initiative as aligning U.S. prices with the lowest in developed nations.

Industry analysts note the voluntary nature of participation marks a shift from prior administration efforts. “Companies are choosing to engage rather than face mandated price caps,” said a healthcare analyst. The platform displays percentage savings and generates coupons for consumers, with the administration touting “massive immediate savings to millions.”

Implications for Patients and Industry

For Americans with high out-of-pocket costs, the expansion could provide relief, especially for those with medications not fully covered by insurance. However, some industry groups have historically resisted price controls, and the long-term sustainability remains unclear. “If revenue pressure mounts, participation may become contentious,” noted a market observer.

Attempts to reach the Pharmaceutical Research and Manufacturers of America for comment were unsuccessful. As of now, no major public debate has emerged, but the policy’s reliance on tariff exemptions ties drug pricing to trade policy, adding a layer of complexity. The announcement is expected later today.

Correction: A previous version of this article misstated the discount on Merck’s drug; it is 74%, not 75%.